Effect of mesalazine combined with tanshinone on inflammatory cytokines and hypercoagulation status in patients with ulcerative colitis

• Main Authors: De-Shan Xiong, Yong-Bing Wang
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2016-11-01
• Series: Journal of Hainan Medical University
• Subjects: Mesalazine; Tanshinone; UC; Inflamamtory cytokine; Hypercoagulation status
• Online Access: http://www.hnykdxxb.com/PDF/201622/19.pdf

Objective: To explore the effect of mesalazine combined with tanshinone on the inflammatory cytokines and hypercoagulation status in patients with ulcerative colitis (UC). Methods: A total of 70 patients with UC who were admitted in our hospital from January, 2014 to January, 2016 were included in the study and randomized into the observation group and the control group. The patients in the two groups were given mesalazine enteric-coated tablets, 1.0 g/time, po, 3 times/d. On this basis, the patients in the observation group were given tanshinone, 1.0 g/time, po, 3 times/d. Eight-week treatment was regarded as one course. The morning fasting venous blood before treatment, 4 and 8 weeks after treatment in the two groups was collected. The immunoturbidimetry was used to detect the serum CRP level. ELISA was used to detect TNF-α and IL-6 levels. The full automatic coagulation function apparatus was used to detect APTT and FIB. The full automatic blood routine analyzer was used to detect PLT, MPV, and PAG. ELISA was used to detect D-D. Results: CRP, TNF-α, and IL-6 levels 4 and 8 weeks after treatment in the two groups were significantly reduced when compared with before treatment (P<0.05), and the reduced degree in the observation group was significantly superior to that in the control group (P<0.05). APTT and MPV 4 and 8 weeks after treatment in the two groups were significantly elevated, while FIB, PLT, PAG, and D-D were significantly reduced when compared with before treatment (P<0.05). Conclusions: Mesalazine combined with tanshinone can inhibit the inflammatory reaction in UC patients, and reduce the hypercoagulation status, with a satisfactory efficacy.